The RIO study tested whether broadly neutralizing antibodies could safely replace daily HIV therapy. In a rigorously designed trial, 75% of participants maintained viral suppression for 20 weeks after stopping antiretrovirals. The findings mark a pivotal step toward potential HIV remission and more flexible treatment strategies.

Dr. Sarah Fidler discusses the challenges of lifelong antiretroviral therapy for HIV and the need for alternative approaches. She highlights broadly neutralising antibodies (bNAbs) as a promising strategy that targets the virus and dormant infected cells, potentially enabling longer-term control by harnessing the immune system’s memory without daily medication.

Respiratory syncytial virus (RSV) is often of increased concern in the autumn and winter months, especially for women who are pregnant, or those with newborns.1 Worldwide, RSV is the second leading cause of death (second to malaria) in children during ...

Initial attempts to develop a HIV vaccine focused on creating a vaccine that would generate neutralizing antibodies against the virus, using portions of the HIV envelope from prototype laboratory isolates. The initial attempts using monomeric envelope proteins of largely laboratory ...

COVID-19 typically causes less severe illness and fewer deaths in children and adolescents compared to adults. Nonetheless, children and adolescents remain susceptible to COVID-19 infection and can transmit to others. In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth ...

IMPAACT 2008 is a phase I/II, multisite, randomized open-label study which evaluates the safety and antiviral activity on HIV-1 DNA levels of VRC01 in infants living with HIV-1 beginning combination antiretroviral therapy (cART). Dr Alka Khaitan (Indiana University School of ...

Each year, 160,000 infants acquire lifelong HIV infection through mother-to-child transmission (MTCT). Dr Alka Khaitan (Indiana University School of Medicine, Indianapolis, IN, USA) joins touchINFECTIOUS DISEASES to discuss the health burden and unmet needs for HIV-1 infection in infants. The presentation ...

Following the recent results from the pivotal Phase III MELODY and Phase IIb trials of nirsevimab in the treatment of respiratory syncytial virus, we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss ...

Following the recent phase III and phase IIb data for nirsevimab in the treatment of respiratory syncytial virus (RSV), we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the unmet needs in ...